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Vaccines
Troy Moon, MD, MPH
Vanderbilt Institute for Global Health
USAID PEER Liberia
◉ Prevention and Control of Vaccine Preventable diseases
◉ Global Impact of vaccines: Successes and challenges
◉ Vaccine fundamentals
○ Basic Immunology
○ Introduction to Vaccinology
Course Object ives
St rategies for  Prevent ion and Cont rol
Eradication: Worldwide interruption of transmission.   
No disease anywhere
Elimination: Interruption of transmission in a substantial 
geographic area.  No endemic cases in the area, 
but still cases elsewhere
Control: Reduction of cases in the geographic area 
of interest
Ingredients for  Eradicat ion/ El im inat ion Program s
◉ Easily recognizable disease
◉ No non-human reservoir
◉ Pathogen is genetically stable
◉ No subclinical infection 
◉ Usually not highly communicable 
Ingredients for  Eradicat ion/ El im inat ion Program s 
◉ An effective, safe (and cheap) intervention
◉ Bold vision and determination           
◉ Resources, administrative skill, flexibility            
Cooperation of the affected populations
SM ALLPOX (Eradicat ion)
Ingredients for  Cont rol
◉ Very distinctive disease
◉ Humans only reservoir
◉ Stable virus
◉ No sub-clinical infection
◉ Transmitted slowly
◉ Vaccine was cheap, easy to administer
◉ Strong vision 
SM ALLPOX 







1977 Last naturally-occurring case
Ali Maow Maalin




1980 Declared eradicated by WHO
2014 Vials of smallpox virus found
NIH cold room being renovated
2019 Gas explosion and fire
State Research Center of Virology
Koltsovo, Siberia
2019 Continuing debate whether two stocks
of smallpox virus (US, Russia) should be destroyed
POLIO
Ingredients for  Cont rol
◉ Easily recognized disease
◉ No non-human reservoir
◉ 3 pathogens genetically stable
◉ MUCH sub-clinical infection
◉ Very transmissible
◉ Vaccine effective –
○ needs several doses
○ easy to administer (oral drops)
○ Cheap
○ but can revert to virulence
◉ International commitment
POLIO
◉ Three individual and immunologically-distinct wild polio 
virus strains (WP1, WP2, WP3)
◉ Symptomatically all the same, however genetic 
differences that require each one to be eradicated
◉ OPV is a weakened but live virus vaccine, meaning you 
are giving the recipient a polio virus.  In very small 
number every year, reverts to full virulence and causes 
Vaccine Derived Polio Virus (VDPV)
POLIO ENDGAM E
1988    Global Polio Eradication Initiative launched
2012 WPV3 last time seen, presumed eradicated
2015 WPV2 declared eradicated globally
2016 tOPV replaced with bOPV (serotypes 1 & 3)
2019 WPV3 declared eradicated     
Wild poliovirus (WPV1) continues to circulate
OPV-derived viruses circulating in Africa, SE Asia, China
2016 IPV being introduced into vaccine programs globally
Global  POLIO Eradicat ion 
◉ Political instability, wars
◉ Religious and political opposition
◉ Immunization fatigue






Role of  Inact ivated Pol io Vaccine ( IPV)
◉ Every country that has eliminated polio used OPV to do it;
because it induces local immunity in the intestinal tract against 
polio.
◉ IPV induces only very low-level immunity and cannot interrupt 
wild type transmission in the environment 
◉ Fever to 40ºC
◉ Rhinorrhea
◉ Cough
◉ Rash (as pictured)
◉ Conjunctivitis (as pictured)














Which vi rus is M OST l ikely cause of  sym ptom s?
M easles
Ingredients for  Cont rol
◉ Distinctive disease
◉ No non-human reservoir
◉ Virus is genetically stable
◉ No subclinical infection
◉ Right conditions for elimination or eradication 
programs
◉ One of the most contagious viral infections.  Infecting 90% 
of susceptible contacts
◉ Spread during asymptomatic phase
◉ Can live 2 hours or longer in the air after an infected 
person coughs or sneezes
◉ Much more easily spread than COVID-19
M easles
Complications of measles
◉ Otitis media ~1 in 10
◉ Pneumonia ~1 in 10
◉ Diarrhea ~1 in 10
◉ Acute encephalitis ~1-1000
◉ Death ~2 per 1000
M easles
Prevention
○Education of health care personnel and community
○Vaccination
○Nutrition (Vitamin A supplementation)
○Treatment of underlying disease (eg. HIV)
M easles
◉ An acute viral hemorrhagic fever
◉ Originated in Central Africa
◉ Spread by aedes aegypti 
mosquito
◉ Monkeys can also be infected
Yel low Fever
◉ Incubation period is 3-6 days






◉ Death can occur on days 7-12 of 
illness
Yel low Fever





◉ Highly effective vaccine
◉ Could be compatible for 
elimination or control 
strategies
Yel low Fever
Ingredients for  Cont rol
1851 Fi rst  In ternat ional  Sani tary Conference (in ternat ional  
cooperat ion regarding 
quarant ine to prevent  cholera and other  problem s)
1905 Yel low Fever  and M alar ia cont rol  Panam a
(Wi l l iam  Crawford Gorgas)

Global Impact of Vaccines: 
Successes and Challenges 







GAVI ’S IM PACT
◉ Increased childhood survival 
○ Halved childhood mortality by preventing approximately 13 million deaths
○ Marked decline in incidence of deadly and debilitating infectious diseases.
◉ National Development thrives.
○ For every US$ 1 invested in vaccines in Gavi-supported countries, there is a US$ 
54 return in savings from averted illness and broader societal benefits. 
◉ Global health security improves.
○ In the face of global challenges, such as climate change, urbanization, human 
migration, fragility and conflict, Gavi has helped countries broaden vaccine 
coverage and improve health systems. 

Berkeley SAGE Presentation October 2019
Berkeley SAGE Presentation October 2019
M ajor  Chal lenges to GVAP
◉ Accelerating urbanization
◉ Migration and displacement
◉ Conflict and political instability
◉ Vaccine unaffordability in middle-income countries
◉ Unexpected vaccine supply shortages both locally 
and globally
◉ Rising vaccine hesitancy 
M easles Highlights Challenges in Vaccine Delivery

















































































































































































































































◉ Immunity- the ability of an organism to resist an infection or 
toxin.  The human body must be able to differentiate “self” 
from “non-self” (eg: bacteria, viruses, pollens)
◉ Antigen- anything that triggers an immune response
○ entire pathogen (bacteria,virus); 
○ toxin expressed by pathogen; 
○ piece of a pathogen (capsular polysaccharide)
◉ Immune system has two overlapping subsystems:
○ Innate immune system
○ Adaptive immune system
Im m une system  overview
◉ Also called “non-specific” or “inborn” immune system
◉ Functions as the first line of defense against infection
◉ Response is non-specific
Innate Im m une System
◉ Non-specific barriers
○ Skin, saliva, mucous
◉ Soluble factors
○ Complement proteins,






Com ponents of  t he Innate Im m une System
◉ Constantly evolves as we encounter new antigens
◉ Creates targeted response (antigenic specificity) to antigens
◉ Takes longer to develop than innate immunity because it is antigen-
specific
◉ Said to have “memory” because it learns by experience and 
responds to previously seen antigens
Adapt ive Im m une System
◉ B-Cells
○ Secrete antibodies
○ Become memory cells
◉ T-Cells
○ Cell mediated immunity
○ Various roles
■ Hunt and destroy 
abnormal cells (cytotoxic 
t-cells)
■ Help activate B-cells 
(helper T-Cells)
◉ Antigen-presenting cells
Com ponents of  t he Adapt ive Im m une System
◉ A substance used to stimulate 
production of antibodies and provide 
immunity against one or several diseases
◉ Prepared from the causative agent, its 
products, or a synthetic substitute
◉ Treated to act as an antigen without 
inducing disease
◉ Vaccines stimulate B and T-Cells 
(adaptive immunity) to produce long-
lasting immunity
What  is a Vaccine?
Inactivated:
◉ Vaccine that is not live
◉ May be composed of toxoids, 
killed virues, or recombinent 
proteins
◉ Not infectious, but still antigenic
Live-Attenuated:
◉ Weakened microbes
◉ Mimic natural infection 
without causing the disease
Inact ivated vs. Live- at tenuated Vaccines
Inactivated:
◉ Vaccine that is not live
◉ May be composed of toxoids, killed 
virues, or recombinent proteins
















Inact ivated vs. Live- at tenuated Vaccines
Advantages:
◉ Cannot replicate, so cannot cause 
infection
◉ Safe even in immunocompromised 
persons
Disadvantages:
◉ Produce weaker immune response 
than a live vaccine
◉ Induce mostly humoral response 
(Abs) with little cellular immunity
◉ Require multiple doses (a priming 
dose and additional doses to 
induce adequate immunity)




◉ Induce strong, long-lasting immune 
cellular and humoral response
◉ Schedules often have repeat dosing 
to ensure a large percent of 
population is truly immunized 
(measles needs 95% for ehrd 
immunity)
○ People may miss dose or some 
people may not respond well to 
first dose
Disadvantages:
◉ Generally need caution when 
giving to immunocompromised 
patients
◉ May cause mild versions of te 
disease you are trying to prevent 
(eg: varicella vaccine may cause a 
rash 10 days after vaccination)
◉ Oral polio vaccine can rarely revert 
to a virulent form and cause 
disease
Live- At tenuated Vaccines

Get The App!
You can download The Vaccine Handbook mobile app for 
FREE from the app store (iphone users only)!
The app is fully searchable, allows for bookmarking, 
highlighting and annotation, and contains hyperlinks to 
valuable content from nonprofit and governmental sources.
The Vaccine Handbook, print edition, is also available for 
purchase.  The 9th edition will be released May 2020.
◉ Polysaccharide vaccines are made 
using a sugar molecules from the 
outer coating of a bacterium (part 
of its capsule)
◉ Stimulates antibody response to 
capsule of the bacterium, which 
aids the immune system removing 
the bacteria
Limitations
◉ Not immunogenic in children <2 years
◉ Do not induce long-lasting immunity
◉ Repeated doses may not provide 
boost
○ Repeated doses (>3 in a lifetime) 
or too close together (<5 years) 
may actually reduce the immune 
response
◉ Pneumococcal-23
○ Reserved for children >2yrs with 
asplenia
○ Or persons >65 years of age
Inact ivated Polysacchar ide vs.
Inact ivated Conjugate vaccines
◉ Conjugate vaccines are made by 
combining a protein (antigen or 
toxoid) from a pathogen with the 
polysaccharide
◉ Conjugation helps promote a more 
robust immune response
◉ No worries giving to 
immunocompromised patients
Advantages
◉ Immunogenic in kids <2 years and 
good in adults >65 years
◉ Do induce long-term immune 
memory
◉ Repeated doses “boost” the immune 
resposne
Eg: Pneumococcal conj; Diptheria, 
Tetanos, HIB,
Inact ivated Polysacchar ide vs.
Inact ivated Conjugate vaccines







◉ Residuals (Trace 
components)
Vaccine Com ponents
Antigens are the components of a vaccine that induce immunity.
○ Portion of disease-causing organism
○ Modified toxin from the organism
○ Live but weakened virus
Ant igens (aka im m unogens)
Adjuvent:  help generate a stronger immune response.  By using 
adjuvent you can use less antigen or give fewer vaccine doses for 
the same effect.
○ Aluminum salts and oil-in-water emulsions most common
Stabilizers: maintain vaccine potency during storage. Protect 
against extreme cold or heat. Provide a bulking matrix so the small 
amount of antigen does not stick to the vial wall.
○ Sugars (sucrose), amino acids (glycine), and proteins (gelatin-
bovine) are most common
Addi t ives
Preservatives:  Keep vaccines safe for injection.  Includes 
antimicrobial agents added to inactivated vaccines to prevent 
growth of bacteria or fungi, especially in a multi-dose vial of 
vaccine.
○ Thimerosol is common preservative.  Causes concern due to 
mercury content.  However, made from ethylmercury and not 
methylmercury (the mercury found in fish and toxic at high 
levels)
Addi t ives
Leftover products from the manufacturing process that may be 
present in final vaccine.  
Examples include formaldehyde or antibiotics, such as 
streptomycin.
Residuals
◉ Some individuals have a bad 
reaction to a vaccine, just as 




○ Soreness at injection site
○ Prolonged crying
◉ Serious AE’s can be found in 
insert for vaccine
Vaccine Adverse Events (AE)
Contraindications and Precautions
Advisory Committee on Immunization Practices (ACIP)
www.cdc.gov
◉ Defined as 3+ hours of crying 
within 2 days of being 
vaccinated
◉ Neither a precaution or 
contraindication for future 
vaccinations
Prolonged Crying
◉ Worrisome shock like reaction following vaccination, 
where child becomes hypotonic and unresponsive for a 
brief period then returns to baseline
◉ Originally associated with whole-cell pertussis vaccine
◉ No long-term consequences.  Not a contraindication for 
future vaccinations
Hypotonic Hyporesponsive Episode (HHE)
Quiz
Innate Immunity Adaptive Immunity
Saliva
Innate Immunity Adaptive Immunity
• Saliva




Innate Immunity Adaptive Immunity
• Saliva • Helper T-cell
Innate Immunity Adaptive Immunity
Neutrophil
• Saliva • Helper T-cell













































Which vaccine is made of only sugars?
Polysaccharide 
vaccine





Which can be given to children < 2 years of age?
Conjugate
vaccine





Which vaccine does not induce long-term immunity?
Polysaccharide 
vaccine




◉ Adenovirus vector vaccines
○ Chimpanzee adenovirus vector
■ AstraZeneca-Oxford
○ Human adenovirus
■ Johnson and Johnson
■ Sputnik (Russian vaccine)
COVID Vaccines
m RNA Vaccines
https://wapo.st/3m7Viys
